-
01:13:36 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

ABMD Stock News

09/20/22 8:02 AM
Nasdaq : ABMD
Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%
Abiomed announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30- day survival rate of 77% for patients with cardiogenic shock due to myocarditis. This study is an update to a 2020 interim analysis and was announced at the 2022 Transcatheter Cardiovascular Therapeutics...
RHEA-AI
neutral
09/19/22 8:02 AM
Nasdaq : ABMD
Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
Caption: The investigator-led Inova, NCSI and J-PVAD studies all demonstrate an improvement from the historical AMI cardiogenic shock survival rate of approximately 50% when patients are treated with best practices including Impella. "The results of this study demonstrate that when Impella is used and best practices are followed, it is possible to achieve...
RHEA-AI
neutral
09/16/22 8:03 AM
Nasdaq : ABMD
fda approval
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
Abiomed announces two approvals from the U.S. Food and Drug Administration related to clinical research of Impella heart pumps in acute myocardial infarction cardiogenic shock patients. This press release features multimedia. "This landmark trial will be the culmination of over 20 years of research in the interventional therapy of AMI and will apply all...
RHEA-AI
positive
09/13/22 8:02 AM
Nasdaq : ABMD
TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery
Abiomed will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics 2022 Conference, held in Boston from September 16 to 19. Impella will be featured in presentations on topics that include a...
RHEA-AI
neutral
08/16/22 8:02 AM
Nasdaq : ABMD
Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella
Abiomed announces the results of the Restore EF study demonstrate Impella-supported high-risk percutaneous coronary intervention leads to significant improvements in left ventricular ejection fraction, angina symptoms and heart failure symptoms at follow-up. The study, which published online August 12 in JSCAI, builds on the largest clinical data...
RHEA-AI
positive
08/04/22 7:00 AM
Nasdaq : ABMD
ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*
ABIOMED, Inc., a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022. Revenue of $277 million, an increase of 10%, or 12% in constant currency, compared to $253 million in the same period of the prior fiscal year. Worldwide product revenue of $264 million, an increase of 10%, or 12% in...
RHEA-AI
positive
06/14/22 4:30 PM
Nasdaq : ABMD
conferences
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps
Abiomed, Inc. today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m.- 3:30 p.m. ET. Jane Wilcox, Chief of the Section of Heart Failure Treatment and Recovery at Northwestern Memorial Hospital in Chicago and Abiomed' s Vice President, Heart Failure,...
RHEA-AI
neutral
05/31/22 7:00 AM
Nasdaq : ABMD
conferences
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference
Abiomed, Inc., a leader in breakthrough heart, lung and kidney support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the William Blair 42 nd Annual Growth Stock Conference on Monday, June 6, 2022 at 2:00pm CT. Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical...
RHEA-AI
neutral